About this Research Topic

Background

Biologics have become essential medical treatments for many progressive, debilitating, or life-threatening diseases. In contrast to these benefits, their ability to trigger unwanted humoral and cellular responses has the potential to reduce their effectiveness or harm patients and, remains a challenge for drug developers and clinicians. In the case of life-saving therapeutics, the development of anti-drug antibodies (ADA) poses a serious threat. Indeed, in the case of the clotting-disorder Haemophilia A, protocols of de-sensitization to recombinant FVIII have been established to circumvent the drug’s immunogenicity by establishing antigen-specific tolerance. Of equal concern, the emergence of ADA or cellular immune responses against protein therapeutics and novel modalities such as gene therapy, gene editing and cellular therapy products can significantly impair treatment efficacy and result in loss of benefit to patients.

Consequently, to comprehend the underlying mechanisms of unwanted immunogenicity, design and implement mitigation strategies has become key to drug innovation. Over the past decades, the dramatic acceleration of biologics development provided opportunities to identify the numerous immunogenicity risk factors at play. Those are commonly referred to as product-, treatment- and patient-related risk factors. The capability to mitigate a risk inherently depends on its category. Whilst product-specific considerations exist, the ability to use loading doses, dose through, and apply comedication does happen, now with higher frequency in clinical trials. The establishment of validated methods to measure anti-drug cellular and humoral immune responses during clinical trials has enabled us to closely monitor patients for immunogenicity, identify any potential efficacy or safety issues and intervene early on. Approaches that induce tolerance to specific antigens have been successful in restoring immune tolerance to proteins used for therapy. Additionally, co-medication and/or co-administration of one or more biologics with immune-suppressive properties have proven to control the development of ADA and rescue life-saving drugs.

However, as not all treatments can be adjusted in the clinic, the main opportunities to reduce the immunogenicity risk present themselves at the drug design phase. The overall risk associated with a product depends on several of its features: 1) critical quality attributes such as its propensity to aggregate, likelihood to undergo post-translational modifications, presence of manufacturing process impurities that could act as adjuvants; 2) intrinsic immunogenicity of protein sequences determined by the presence of strong T cell epitopes; 3) capacity of RNA products to trigger the innate immune system; 4) pre-existing immunity to the protein, the viral vector such as AAV in gene therapy products, or part of the vector such as polyethylene glycol in lipid nanoparticle; 5) poly-specificity, which has also been shown to increase immunogenicity of monoclonal antibodies.

Over time, a suite of elaborate in silico and in vitro tools have been developed to assess these multiple product-related risks, compare lead compounds, and select drug candidates with the most favorable immunogenicity risk profile. These tools include prediction algorithms (epitope binding, epitope presentation, clinical immunogenicity, epitope foreignness), cell-based assays of multiple formats, and variable degrees of throughput and potential for automation. The creation of increasingly complex biologic modalities challenges academic and biopharmaceutical scientists to continually re-think existing tools to de-risk drugs by design, investigate new methods to monitor immune responses, and seek innovative approaches to mitigate immunogenicity in the clinic.

The aim of this collection is to provide readers with current advances in the field.

Solicited articles will highlight recent successes, discuss gaps, limitations and articulate how current thinking and knowledge and novel technologies including artificial intelligence, are driving continuous improvement of immunogenicity risk assessment, monitoring, and mitigation across all biologics modalities.

This collection focuses on:

• Immunogenicity of therapeutics, including but not limited to therapeutic proteins, cell, gene therapy, peptides and oligonucleotides-based products.
• Non-clinical immunogenicity risk assessment: in silico algorithms and prediction models, fit-for-purpose validation, standardization of in vitro assays, application of automation and high throughput approaches to in vitro tools, 3D in vitro systems
• Immunogenicity monitoring: novel quantitative analysis platforms, observed clinical immunogenicity, contribution to treatment decisions
• Clinical consequences of immunogenicity: loss of clinical responses, hypersensitivity, immune-complexes-related diseases
• Mitigation of immunogenicity: mitigation by design, antigen-specific and non-antigen-specific tolerance induction, combination therapies

All Topic Editors declare no conflict of interests

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Classification
• Clinical Trial
• Curriculum, Instruction, and Pedagogy
• Editorial
• General Commentary
• Hypothesis and Theory
• Methods
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Classification
• Clinical Trial
• Curriculum, Instruction, and Pedagogy
• Editorial
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: Immunogenicity Risk Assessment, oligonucleotides, Immunogenicity, Biologics, Monitoring and Mitigation, Anti-drug antibodies, Protein therapeutics, gene editing, gene therapy, cell therapy, mRNA-LNP, generic peptides

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

• What is a Research Topic?

  Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

  Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

• Why does Frontiers publish Research Topics? 

  The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

  Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

• Why are Research Topics important for journals?

  As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

  A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

• How do we ensure the quality of articles within Research Topics?

  Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

  In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

• What are the benefits of publishing my article in a Research Topic?

  Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

  As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

  Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

   
• What types of articles can be published in a Research Topic?

  Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

  Check available article types here 

• Can I suggest a new Research Topic? 

  Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

  Suggest your topic here 

• Who leads a Research Topic? 

  A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

  The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

• What is the role of a topic editor?

  As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

   

  You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

• What support will I receive when editing a new Research Topic? 

  As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

• As a junior researcher, can I be involved in editing a Research Topic? 

  If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

• Can I get a certificate for editing a Research Topic?

  Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

• Who will I collaborate with?

  Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

• How long does it take to publish a Research Topic?

  As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

  Find out more about our Research Topics

• What fee support is available to authors publishing in a Research Topic?

  Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

  Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

• Will there be a printed version of my Research Topic?

  In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.